AI-generated · cited to primary sources · not investment advice · How we research
Fortis Health.
Our verdict on Fortis Health. isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
For the 9-month period, hospital business operating margins reached 22.2%. While slightly below the 22.5% stretch target, it shows significant improvement from 20% in the previous year. (2 in progress across 2 tracked commitments)
“So I think there is a possibility we can see higher margin improvement than what we have guided at the beginning of the year. To quantify it will be a bit higher.”
Hospital occupancy improved to 69% in Q1 FY26, trending towards the full-year target of 70-71%. (1 in progress, 1 met, 1 missed across 3 tracked commitments)
“Vivek Goyal: Yes, we are aiming around 70%-71% occupancy level at the overall level because this brownfield expansion is on the existing facility and these hospitals anyway operating at 50% type of occupancy level.”
Management has updated the timeline for the remaining capacity addition at Manesar to Q4 FY26. 175 beds were added till Dec'25. (1 revised across 1 tracked commitment)
“But at the same time, we are also going to expand and start the expansion work for creating further beds so that the capacity can be taken to 300 beds... So over the next 3 to 4 years, we should see this as a high-end 300-bedded super speciality hospital”
Fortis plans to install an oncology block at the Jaipur facility to improve margins and clinical offerings. — target: Oncology block installation
“So these type of specialty takes some time. And generally, it is 18 to 24 months' time. So in the next year budget, we were planning to put something for Jaipur.”
The company plans to add 4 new robotic machines across the network within the current year at a capex of approximately INR 12 crores per da Vinci unit. — target: 4 robotic machines
“So we have approximately 15 robotic machines across our network right now, and we are in the process of getting another 4 this year.”
See the full cited Management analysis of Fortis Health.
How durable is the business?
The company is aggressively expanding its scale through brownfield additions (900 beds planned) and a new O&M agreement to manage 700 beds for Gleneagles India. (5 expanding)
“36 Healthcare Facilities; 6,000+ Operational Beds; 400 diagnostics labs.”
International patient revenue grew 26% to INR 169 Cr, increasing its share of total hospital revenue from 7.7% to 8.1%, signaling strong recovery in medical tourism. (1 expanding)
“International Patient revenues grew 26% to INR 169 Cr in Q2 FY26 vs INR 135 Cr in Q2 FY25. The business contributed to 8.1% to overall hospital business revenues”
The diagnostics business (Agilus) saw revenue growth of 4.0% for the year, with a significant margin expansion to 19.8% from 17.3%. (5 expanding across 1 engine)
“the diagnostics business net revenue reported a growth of 7.3% to INR327 crores... Operating EBITDA margin gross revenue stood at 23.1% versus 14.4% in Q3 of financial year '25.”
Fortis is deepening its cluster presence in Punjab through the acquisition of Shrimann Superspecialty Hospital, adding 228 beds with potential to reach 450. (4 expanding, 1 shifted)
“Fortis signed definitive agreement in February 2025 to acquire Shrimann Superspecialty Hospital in Jalandhar, Punjab... This acquisition will add 228 beds to our network.”
International patient revenue grew 21% YoY, maintaining a stable share of the hospital business at approximately 7.9%. (2 expanding, 3 stable)
“So I mean the percentage of revenue, this has been stable at about 8%, 9% and somewhere as total revenue percentage. It has remained in that level, and it is likely to remain in that level.”
See the full cited Business Model analysis of Fortis Health.
Where does growth come from?
ARPOB growth is accelerating significantly, reaching INR 2.65 Crores per annum in Q1 FY26, a 10.2% increase compared to the previous year, driven by a better specialty mix and complex cases like robotic surgeries. (2 accelerating, 3 steady across 5 signals)
“Our hospital business recorded a 4.5% increase in ARPOB, reaching INR2.56 crores per annum. The growth in ARPOB was supported by increase in share of complex cases reflected in, for instance, a 52% year-on-year increase in robotic surgeries.”
International patient revenue is accelerating, growing 21% YoY in the most recent quarter, slightly higher than the previously reported 19% trend. (3 accelerating, 1 decelerating, 1 steady across 5 signals, 1 leading indicator)
“International Patient revenues grew 19% to INR 156 Cr in Q3FY26 vs INR 132 Cr in Q3FY25.”
Fortis is investing in advanced medical technology, such as robotic surgical systems, to improve patient outcomes and attract more complex surgical cases.
“Fortis Hospital, Manesar, launched the Da Vinci Xi Robotic Surgical System... Fortis Hospital, Nagarbhavi, Bengaluru, launched the next-generation Mako Robotic System for advanced knee joint replacement surgeries”
The diagnostic arm (Agilus) is seeing a recovery in margins and a shift toward preventive health. Preventive portfolio revenue grew 13% in FY25, now contributing 11% of total diagnostic revenue, up from 10% in the prior year. (5 accelerating across 5 signals, 1 leading indicator)
“The revenue contribution from preventive portfolio has increased to 12% in Q3 from 10% in Q3 of '25, while the contribution from specialized portfolio has increased to 35% from 33%”
Profitability is improving significantly as the company fills more beds, with hospital profit margins rising to 21.7% this quarter. — Hospital Operating EBITDA Margin: +170 bps YoY
“The hospital business operating EBITDA margins have improved from 20% in quarter 3 of '25 to 21.7% in quarter 3 of financial year '26”
See the full cited Future Growth analysis of Fortis Health.
What could break the thesis?
The BG Road facility is struggling with low patient occupancy, which acts as a drag on the overall hospital segment performance. [EXECUTION]
“Except I will say BG Road, which is still struggling. And we are working on how to improve the occupancy level of BG Road.”
International patient revenue is vulnerable to unpredictable global political situations, making it a risky segment to rely on for steady growth. [DEMAND]
“Because the international traffic is subject to so many other geopolitical situations, which are continuously evolving right now, so I think one cannot really bank on that.”
The trajectory is easing for CGHS as positive results are appearing, but ECHS remains uncertain due to lack of clarity on drug pricing and new circulars. (1 easing)
“So we have started seeing the positive result from the CGHS particularly. ECHS, the circular is new, and there is still some doubts which need to be cleared.”
The integration is now progressing well under a new operation and management services agreement for five hospitals and a clinic. Management expects to eventually evaluate a full merger/integration. (1 easing, 1 intensifying)
“The integration of Gleneagles units under the agreement with Fortis is progressing well.”
The Manesar facility is showing strong recovery. It is currently at 40% occupancy with only 90 beds commissioned; management expects to reach breakeven even before hitting 50% occupancy, which is targeted by year-end. (1 easing)
“Regarding Manesar... The exit should be at least 50%-plus occupancy. I think so. Even before that, we should expect a breakeven.”
See the full cited Risk analysis of Fortis Health.
Fortis Health. analysis by filing period
Read the full thesis on Fortis Health.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.